Physician profile
Lewis D Mitchell
NPI 1124197090
$5,107.97
in general payments reported to CMS, 2019-2025
39 companies · $25.71 in 2025
The $25.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $890 · 2021: $957 · 2022: $933 · 2023: $824 · 2024: $474 · 2025: $25.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $787.75 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $551.58 | 2019-2024 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $460.26 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.00 | 2019-2024 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $400.49 | 2019-2024 | Breztri, Airsupra |
| Abbvie INC. | $368.36 | 2020-2024 | |
| Abbott Laboratories | $269.35 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Merck Sharp & Dohme LLC | $207.22 | 2020-2024 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $177.58 | 2019-2023 | Shingrix, Bexsero, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $160.43 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.32 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $110.05 | 2019-2021 | |
| Amarin Pharma, INC. | $106.23 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $102.91 | 2021 | |
| Astellas Pharma US INC | $91.78 | 2019-2024 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.